Janssen Ends Development of Fulranumab for Osteoarthritis Pain

Janssen Pharmaceuticals will terminate its license with Amgen for fulranumab—ending a collaboration stretching back 8 years that could have generated up to $435 million for Amgen. As a result, the Johnson & Johnson entity said, its Janssen Research & Development unit will end Phase III development of the candidate for osteoarthritis pain. In a statement issued late yesterday after the close of financial markets, Janssen said it was not responding to safety concerns from its Phase III studies, but realigning its clinical development programs with its strategic portfolio. Janssen has identified its five areas of therapeutic focus as cardiovascular and metabolic diseases, immunology, infectious diseases and vaccines, neuroscience, and oncology. While the company’s website includes pain management within neuroscience, Janssen’s statement hinted of a narrowing of its focus within that…


Link to Full Article: Janssen Ends Development of Fulranumab for Osteoarthritis Pain